Study of Ibrutinib in Combination With Rituximab in Previously Untreated Subjects With Follicular Lymphoma
Public ClinicalTrials.gov record NCT01980654. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Multicenter, Open-Label, Phase 2 Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Combination With Rituximab in Previously Untreated Subjects With Follicular Lymphoma
Study identification
- NCT ID
- NCT01980654
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- Pharmacyclics LLC.
- Industry
- Enrollment
- 80 participants
Conditions and interventions
Interventions
- Ibrutinib Drug
- rituximab Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Nov 30, 2013
- Primary completion
- Oct 31, 2017
- Completion
- Oct 31, 2017
- Last update posted
- Apr 15, 2019
2013 – 2017
United States locations
- U.S. sites
- 12
- U.S. states
- 8
- U.S. cities
- 11
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Providence Saint Joseph Medical Center | Burbank | California | 91505 | — |
| City of Hope | Duarte | California | 91010 | — |
| UCLA Medical Center | Los Angeles | California | 90095 | — |
| Stanford University, Stanford Care Center | Stanford | California | 94305 | — |
| Southeastern Regional Medical Center | Newnan | Georgia | 30265 | — |
| Community Health Network Community Regional Cancer Center North | Indianapolis | Indiana | 46256 | — |
| Comprehensive Cancer Centers of Nevada | Henderson | Nevada | 89074 | — |
| Memorial Sloan-Kettering Cancer Center | New York | New York | 10065 | — |
| Weill Cornell Medical College New York-Presbyterian Hospital | New York | New York | 10065 | — |
| Mid-Ohio Oncology/ Hematology Inc | Columbus | Ohio | 43219 | — |
| Tennessee Oncology, PLLC The Sarah Cannon Research Institute | Nashville | Tennessee | 37203 | — |
| The University of Texas MD Anderson Cancer Center | Houston | Texas | 77030 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01980654, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Apr 15, 2019 · Synced Jul 22, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT01980654 live on ClinicalTrials.gov.